Fry David C, Wartchow Charles, Graves Bradford, Janson Cheryl, Lukacs Christine, Kammlott Ursula, Belunis Charles, Palme Stefan, Klein Christian, Vu Binh
Roche Research Center , 340 Kingsland Street, Nutley, New Jersey 07110, United States.
Roche Diagnostics GmbH , Nonnenwald 2, Penzberg 82377, Germany.
ACS Med Chem Lett. 2013 May 24;4(7):660-5. doi: 10.1021/ml400062c. eCollection 2013 Jul 11.
Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead identification stage. Application of the fragment-based approach may help toward success with this target class. To provide an example toward understanding the potential issues associated with such an application, we have deconstructed one of the best established protein-protein inhibitors, the Nutlin series that inhibits the interaction between MDM2 and p53, into fragments, and surveyed the resulting binding properties using heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR), surface plasmon resonance (SPR), and X-ray crystallography. We report the relative contributions toward binding affinity for each of the key substituents of the Nutlin molecule and show that this series could hypothetically have been discovered via a fragment approach. We find that the smallest fragment of Nutlin that retains binding accesses two subpockets of MDM2 and has a molecular weight at the high end of the range that normally defines fragments.
蛋白质-蛋白质相互作用(PPI)系统是药物发现中丰富的潜在靶点来源,但从历史上看,已证明其具有挑战性,尤其是在先导化合物识别阶段。基于片段的方法的应用可能有助于在这类靶点上取得成功。为了提供一个例子来理解与这种应用相关的潜在问题,我们将已确立的最佳蛋白质-蛋白质抑制剂之一、抑制MDM2和p53之间相互作用的Nutlin系列分解为片段,并使用异核单量子相干核磁共振(HSQC NMR)、表面等离子体共振(SPR)和X射线晶体学研究了所得的结合特性。我们报告了Nutlin分子每个关键取代基对结合亲和力的相对贡献,并表明该系列理论上可以通过片段方法发现。我们发现,保留结合能力的Nutlin最小片段可进入MDM2的两个亚口袋,其分子量处于通常定义片段的范围的高端。